At o2h discovery, our expertise lies in tailoring a range of proven high-quality, hit-finding approaches for your target of interest. We have a track record of working with “me too” and “undruggable” class of targets, this coupled with a good understanding of potency to efficacy translation, we can provide an integrated suite of high-quality assays.
Our strategy and partnership will first involve a comprehensive understanding of the target biology followed by recommendations of suitable screening platforms utilizing various label and label-free technologies. These strategies can be run concurrently or independently to identify promising hit series for further advancement by combining orthogonal validation assays for compound re-confirmation and prioritization.
Our o2h scientists can develop bespoke assays for diverse target classes including G protein-coupled receptors (GPCRs), transporters, ion channels, enzymes and protein-protein interactors (however not limited). Our expertise encompass a wide range of biophysical, biochemical and cell-based (functional and phenotypic) screening approaches that is integrated and run alongside medicinal and synthetic chemistry capabilities.
We could utilize our proprietary fragment-based library designed by our medicinal chemists in conjunction with academic computational chemists (or) use commercially procured (or) proprietary client libraries for screening. Compounds that show promising interaction with the target in the initial screening are further validated through various orthogonal experiments to confirm their activity and specificity. This helps to filter out false positives and identify true hits.
To know more about our integrated drug discovery services offering or to request our brochure, please reach out to us at discovery@o2h.com.
